BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Vetter invests $285 M in new clinical manufacturing site in US

June 30, 2025 | News

Production site expected to be fully operational by the end of 2029



Vetter, a globally operating Contract Development and Manufacturing Organisation (CDMO), recently celebrated the start of construction for its new clinical manufacturing site in Des Plaines with an official groundbreaking ceremony.

The independent pharmaceutical service provider received the building permit for the new site in April of this year. With an investment of approximately $285 million, this new facility underscores Vetter's dedication to delivering high-quality services and drug products during early clinical development.

Upstream and ground preparation work on the premises started back in April. Vetter's construction plans include a 160,000 square foot clinical production facility for aseptic manufacturing. The site will also feature new process areas for material preparation and compounding.

Additional buildings will include supporting services like storage, laboratories, and offices. The clinical site is expected to be fully operational by the end of 2029 with subsequent relocation plans of Vetter's current clinical operations in Skokie.

The existing buildings in the Des Plaines area will be retained. With 19-acres the property also provides ample space for future expansion opportunities. These will depend on global market developments and customer demand, as well as additional investment projects currently underway at Vetter in Germany and Austria.